Abstract

Community-acquired pneumonia (CAP) is a worldwide leading cause of death. Recognized risk factors in some severe cases have not been identified. Lymphocytopenia has been frequently described in CAP. Since IL-7, membrane-bound receptor (IL7Rα;CD127) and soluble IL7Rα (sIL7R) are critical in lymphocytes homeostasis, in this work we aimed to evaluate the involvement of the IL-7/IL7Rα axis in the severity of adult CAP, since it has not been explored. The IL7Rα SNPs rs6897932, rs987106, and rs3194051 SNPs in IL7α were genotyped, the systemic expression of the IL7R gene, sIL7R, IL-7, and levels of peripheral IL7Rα+ T lymphocytes were quantified in 202 hospitalized CAP cases. rs3194051GG was more frequent in non-survivors than in survivors; rs987106TT was more frequent and rs3194051AA less frequent in patients at intensive care unit (ICU) than in those not admitted to ICU. IL7Rα gene expression was lower in non-survivors than in survivors, and in severe than in mild cases. CD3+CD127+ lymphocytes were lower in severe than in mild cases; in non-survivors than in survivors and in ICU than in non- ICU admitted cases. sIL7Rα plasmatic levels were higher in non-survivors than in survivors, and in severe than in mild cases. rs6897932CC, rs987106AA and rs3194051GG carriers showed the highest while rs6897932TT showed the lowest sIL7Rα levels. The AUC of sIL7Rα levels predicting 30-day mortality was 0.71. Plasma IL-7 levels were lower in ICU-admitted than in not ICU-admitted and in non-survivors than in survivors. No additional association was detected. In conclusion, rs3194051GG and rs987106TT IL7R genotypes were associated with a poorer prognosis. A significant association between sIL7R levels and SNPs of the IL7R gene is described for the first time in adult CAP. Increased plasmatic sIL7R could contribute to identifying adult CAP cases at risk of death.

Details

Title
IL-7/IL7R axis dysfunction in adults with severe community-acquired pneumonia (CAP): a cross-sectional study
Author
Ampuero, Sandra 1 ; Bahamonde, Guillermo 1 ; Tempio, Fabián 2 ; Garmendia, María Luisa 3 ; Ruiz, Mauricio 4 ; Pizarro, Rolando 5 ; Rossi, Patricio 6 ; Huenchur, Lucía 6 ; Lizama, Luis 1 ; López, Mercedes 2 ; Avendaño, Luis F. 1 ; Luchsinger, Vivian 1 

 Universidad de Chile, Programa de Virología, ICBM, Facultad de Medicina, Santiago, Chile (GRID:grid.443909.3) (ISNI:0000 0004 0385 4466) 
 Universidad de Chile, Programa de Inmunología, ICBM, Facultad de Medicina, Santiago, Chile (GRID:grid.443909.3) (ISNI:0000 0004 0385 4466); Universidad de Chile, Instituto Milenio de Inmunología e Inmunoterapia, Facultad de Medicina, Santiago, Chile (GRID:grid.443909.3) (ISNI:0000 0004 0385 4466) 
 Universidad de Chile, Instituto de Nutrición y Tecnología de los Alimentos, Santiago, Chile (GRID:grid.443909.3) (ISNI:0000 0004 0385 4466) 
 Hospital Clínico Universidad de Chile, Departamento de Medicina, Santiago, Chile (GRID:grid.412248.9) (ISNI:0000 0004 0412 9717) 
 Hospital Lucio Córdova, Santiago, Chile (GRID:grid.412248.9) 
 Complejo Hospitalario San José, Santiago, Chile (GRID:grid.412248.9) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2696535029
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.